CD40L on CD4
IntroductionCD40 ligand (CD40L; CD154) is an inducible costimulatory molecule involved in promoting B-and T-cell responses, and the consequences of human CD40L deficiency are readily apparent in the X-linked form of the hyper-IgM syndrome. 1 CD40L is absent or present at low levels on the surface of circulating CD4 ϩ T cells, whereas its cognate receptor, CD40, is constitutively expressed on the surface of B cells, monocytes, dendritic cells (DCs), endothelial cells, and several other cell types. [2][3][4][5] On B cells, CD40/CD40L interactions initiate a program of B-cell activation, Ig secretion, isotype switching, and B-cell memory formation. Through the up-regulation of major histocompatibility complex class II and costimulatory ligands on antigen-presenting cells, this interaction also plays a critical role in activating T cells and promoting Th1 differentiation by inducing interleukin-12 (IL-12) production. [6][7][8][9][10] It has long been established that CD40L is rapidly expressed on the majority of CD4 ϩ T cells on activation but returns to nearbaseline levels by 24 hours. 11 More recently, it has been reported that a second peak of CD40L expression at 48 hours follows the nadir at 24 hours. 12,13 Although the kinetics of biphasic CD40L expression are identical in human and mouse, it appears that the mechanisms that regulate late-phase expression differ. In the mouse, IL-4 and IL-12 counterregulate the late phase of CD40L expression, with IL-4 inhibiting and IL-12 promoting expression. 13 By contrast, late-phase human CD40L expression is CD28/IL-2-dependent. 14 The biologic impact of biphasic CD40L expression has been investigated in several systems. For example, whereas early-phase CD40L expression promotes B-cell differentiation and antibody secretion in the mouse, sustained expression inhibits these same processes. [15][16][17][18][19] By contrast, early CD40L expression is not sufficient to induce human IL-12p70, which requires both early and late CD40L expression. 12 In addition, constitutive expression of CD40L in transgenic or bone marrow chimeric mice results in a high frequency of T-cell lymphoproliferative abnormalities. 20,21 Collectively, these findings demonstrate that the regulated expression of CD40L is crucial to its normal physiologic function.Although there is little surface expression of CD40L on circulating human or mouse CD4 ϩ T cells, CD40L mRNA is readily detected in unstimulated mouse, but not human, CD4 ϩ T cells. [22][23][24][25][26][27] This suggests a fundamental difference in the regulation of CD40L expression between human and mouse. It has been proposed that the apparent absence of surface CD40L on resting mouse CD4 ϩ T cells is not the result of a lack of CD40L expression but rather to tonic CD40L-CD40 interactions that induce downregulation of the ligand. 28 This premise is based on the observation that naive CD4 ϩ T cells in the CD40 knockout mouse constitutively expresses surface CD40L. 28,29 In the mouse, preformed mRNA presumably accounts for constituti...